FKBP51 acts as a biomarker of early metastasis and is related to carmustine sensitivity in human glioma cells.

OBJECTIVE Given that FK506 binding protein 51 (FKBP51) is upregulated in multiple cancers, we designed the present study to characterize its role as well as underlying regulatory mechanisms in glioma in the presence and absence of the chemotherapeutic carmustine (BCNU). MATERIALS AND METHODS Through lentiviral overexpression and shRNA knockdown of FKBP51, we examined the effects on BT325 glioma cell proliferation, migration and invasion using quantitative reverse transcription PCR (qRT-PCR), CCK-8 assay, flow cytometry, and transwell assay. RESULTS The upregulation of FKBP51 resulted in significantly decreased BT325 cell proliferation and cell viability, cell cycle arrest, reduced BCNU chemosensitivity and AKT pathway inactivation. However, FKBP51-overexpressed BT325 cells showed enhanced migration and invasion, which was supported by corresponding increase in phosphorylated IKKα (p-IKKα), MMP-2, and MMP-9 levels, as well as increased NF-κB p65 nuclear translocation. By contrast, FKBP51-suppressed BT325 cells showed excessive proliferation and BCNU resistance due to increased p-AKT activation and attenuated migration and invasion. CONCLUSIONS We demonstrated that the effects of FKBP51 on BT325 glioma cell proliferation, migration, invasion and BCNU chemosensitization are modulated via the AKT and NF-κB pathways. Furthermore, our findings suggest the potential of FKBP51 as a prognostic glioma biomarker and an indicator of patient response to chemotherapy.

[1]  Chuanlu Jiang,et al.  Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma. , 2018, Cancer letters.

[2]  D. Vertommen,et al.  HBP1 phosphorylation by AKT regulates its transcriptional activity and glioblastoma cell proliferation. , 2018, Cellular signalling.

[3]  J. Liao,et al.  The predictive potential of hyponatremia for glioblastoma patient survival , 2018, Journal of Neuro-Oncology.

[4]  G. Fries,et al.  The FKBP51 Glucocorticoid Receptor Co-Chaperone: Regulation, Function, and Implications in Health and Disease , 2017, International journal of molecular sciences.

[5]  K. Xue,et al.  MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression. , 2017, European review for medical and pharmacological sciences.

[6]  Murray N. Robertson,et al.  Inhibitory Kappa B Kinase α (IKKα) Inhibitors That Recapitulate Their Selectivity in Cells against Isoform-Related Biomarkers , 2017, Journal of medicinal chemistry.

[7]  S. Staibano,et al.  A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma , 2017, Oncotarget.

[8]  A. Toker,et al.  AKT/PKB Signaling: Navigating the Network , 2017, Cell.

[9]  M. Masullo,et al.  FKBP51 employs both scaffold and isomerase functions to promote NF-κB activation in melanoma , 2015, Nucleic acids research.

[10]  Xiaoming Yu,et al.  Androgen receptor signaling regulates growth of glioblastoma multiforme in men , 2015, Tumor Biology.

[11]  K. Liao,et al.  Dihydroartemisinin inhibits cell proliferation via AKT/GSK3β/cyclinD1 pathway and induces apoptosis in A549 lung cancer cells. , 2014, International journal of clinical and experimental pathology.

[12]  S. Tsao,et al.  Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway , 2014, Oncotarget.

[13]  Jun Liu,et al.  PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway , 2014, Genetics and molecular biology.

[14]  Chen Bian,et al.  Expression of estrogen receptors, androgen receptor and steroid receptor coactivator-3 is negatively correlated to the differentiation of astrocytic tumors. , 2014, Cancer epidemiology.

[15]  Erin E. Carlson,et al.  Contribution of FKBP5 Genetic Variation to Gemcitabine Treatment and Survival in Pancreatic Adenocarcinoma , 2013, PloS one.

[16]  K. Rajalingam,et al.  Abstract 837: Identification of non-canonical NF-κB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells. , 2013 .

[17]  M. Willingham,et al.  Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma , 2012, Oncogene.

[18]  M. Galigniana,et al.  FKBP51 and FKBP52 in signaling and disease , 2011, Trends in Endocrinology & Metabolism.

[19]  S. Romano,et al.  The Emerging Role of Large Immunophilin FK506 Binding Protein 51 in Cancer , 2011, Current medicinal chemistry.

[20]  T. Shimura.  Acquired radioresistance of cancer and the AKT/GSK3β/cyclin D1 overexpression cycle. , 2011, Journal of radiation research.

[21]  Ya-Li Yao,et al.  FKBPs in chromatin modification and cancer. , 2011, Current opinion in pharmacology.

[22]  J. Palvimo,et al.  Steroid up-regulation of FKBP51 and its role in hormone signaling. , 2011, Current opinion in pharmacology.

[23]  J. Solassol,et al.  FKBP family proteins as promising new biomarkers for cancer. , 2011, Current opinion in pharmacology.

[24]  R. Dubrow,et al.  Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007 , 2011, BMC Cancer.

[25]  G. Piwien-Pilipuk,et al.  The 90-kDa Heat-shock Protein (Hsp90)-binding Immunophilin FKBP51 Is a Mitochondrial Protein That Translocates to the Nucleus to Protect Cells against Oxidative Stress* , 2011, The Journal of Biological Chemistry.

[26]  A. Bracher,et al.  Structural characterization of the PPIase domain of FKBP51, a cochaperone of human Hsp90. , 2011, Acta crystallographica. Section D, Biological crystallography.

[27]  Geoffrey C Kabat,et al.  Do Steroid Hormones Play a Role in the Etiology of Glioma? , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[28]  Jiu-Chang Zhong,et al.  Suppression of CDK2 expression by siRNA induces cell cycle arrest and cell proliferation inhibition in human cancer cells. , 2010, BMB reports.

[29]  M. Falasca.  PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. , 2010, Current pharmaceutical design.

[30]  H. Frierson,et al.  FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells , 2010, Molecular and Cellular Biology.

[31]  W. Shou,et al.  FKBP51 and Cyp40 are Positive Regulators of Androgen-dependent Prostate Cancer Cell Growth and the Targets of FK506 and Cyclosporin A , 2009, Oncogene.

[32]  Wun-Jae Kim,et al.  Naringin inhibits matrix metalloproteinase-9 expression and AKT phosphorylation in tumor necrosis factor-alpha-induced vascular smooth muscle cells. , 2009, Molecular nutrition & food research.

[33]  Krishna R. Kalari,et al.  FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. , 2009, Cancer cell.

[34]  Wei Wang,et al.  The Phosphatidylinositol 3-Kinase/Akt Cassette Regulates Purine Nucleotide Synthesis* , 2009, Journal of Biological Chemistry.

[35]  K. Tai,et al.  Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1 , 2008, Oncogene.

[36]  J. Skolnick,et al.  Structure‐based classification of 45 FK506‐binding proteins , 2008, Proteins.

[37]  T. Mikkelsen,et al.  FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway. , 2008, Neoplasia.

[38]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[39]  M. Fresno,et al.  Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. , 2005, Oral oncology.

[40]  K. Hess,et al.  Adult glioma incidence trends in the United States, 1977–2000 , 2004, Cancer.

[41]  H. Hsu,et al.  Functional Role of Caspases in Sphingosine‐Induced Apoptosis in Human Hepatoma Cells , 2003, IUBMB life.

[42]  J. McCubrey,et al.  Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy , 2003, Leukemia.

[43]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[44]  G. Kundu,et al.  Matrix metalloproteinase-2: Mechanism and regulation of NF-κB-mediated activation and its role in cell motility and ECM-invasion , 2004, Glycoconjugate Journal.

[45]  Michael Karin,et al.  NF-kappaB in cancer: from innocent bystander to major culprit. , 2002, Nature reviews. Cancer.